Rhythm Maintenance Effect of Calcium Channel Blockers and Beta Blockers in Atrial Fibrillation
Beta blockers provide modest but consistent rhythm maintenance benefit in atrial fibrillation, while non-dihydropyridine calcium channel blockers (verapamil, diltiazem) have no proven antiarrhythmic efficacy for maintaining sinus rhythm.
Beta Blockers: Modest Rhythm Control Agents
Beta blockers are generally not considered primary therapy for maintenance of sinus rhythm in patients with AF and structural heart disease 1, 2, 1. However, the evidence shows they do have measurable rhythm maintenance effects:
Evidence for Rhythm Maintenance
Various beta blockers have demonstrated moderate but consistent efficacy to prevent AF recurrence or reduce the frequency of paroxysmal AF, comparable to conventional antiarrhythmic drugs 1, 2, 1:
Metoprolol (sustained-release): In a placebo-controlled study of 394 patients with persistent AF, showed lower risk of early recurrence after cardioversion and slower ventricular response compared to placebo 1, 2
Atenolol and bisoprolol: More effective than placebo in reducing frequency and duration of paroxysmal AF and reducing probability of relapse after cardioversion 1, 2
Carvedilol and bisoprolol: Produced similar reductions in relapse over 1 year in patients with persistent AF after cardioversion 1, 2
An observational study found beta blockers reduced the risk of developing AF during an average follow-up of 3.2 years 1, 2
Important Caveats
Beta blockers have the advantage of controlling ventricular rate when AF recurs and reduce or abolish associated symptoms, but unawareness of recurrent AF may have disadvantages 1, 2. They may be effective in postoperative patients but potentially aggravate vagally mediated AF 1, 2.
Calcium Channel Blockers: No Rhythm Maintenance Benefit
There is no evidence to support the antiarrhythmic efficacy of calcium channel antagonist drugs (verapamil, diltiazem) in patients with paroxysmal AF 1. These agents function purely as rate control medications:
- They reduce heart rate during an AF attack such that symptoms may disappear despite recurrent AF 1
- One study showed diltiazem reduced the number of AF episodes occurring in a 3-month period by approximately 50%, but this was likely due to rate control masking symptomatic episodes rather than true rhythm maintenance 1
- They have not been found effective for pharmacological cardioversion of recent-onset or persistent AF 2
Clinical Algorithm for Decision-Making
When rhythm maintenance is the goal:
Do NOT use non-dihydropyridine calcium channel blockers (verapamil, diltiazem) as they lack rhythm maintenance properties
Consider beta blockers as adjunctive therapy rather than primary rhythm control:
- Useful in postoperative AF prevention
- Reasonable in patients with coronary artery disease where they serve dual purposes 3
- Acceptable when rate control during AF recurrence is equally important as rhythm maintenance
Use dedicated antiarrhythmic drugs for primary rhythm maintenance:
Key Distinction: Rate vs. Rhythm Control
The fundamental issue is that calcium channel blockers and most beta blockers are rate control agents, not rhythm control agents 4, 5, 6. Recent meta-analyses confirm that both drug classes provide comparable control of mean heart rate in AF 5, but this is distinct from preventing AF recurrence.
The modest rhythm maintenance effect seen with beta blockers appears to be a secondary benefit rather than their primary mechanism, and they remain inferior to dedicated antiarrhythmic drugs for this purpose 7.